A Real-World Study of Recombinant Human Growth Hormone
PediatricsPage Navigation
OBJECTIVE
The research aimed to evaluate the efficacy of recombinant human growth hormone (rhGH) in treating idiopathic short stature (ISS) and growth hormone deficiency (GHD) in children and also to explore the related factors affecting treatment efficacy.
METHODS
This research is on a real-world study where 79 patients with ISS and 95 patients with GHD (both groups pre-puberty) were treated with rhGH for more than one year from January 2010 to September 2019. The growth indexes, such as chronological age (CA), bone age (BA), height standard deviation score (HtSDS), insulin-like growth factor-1 (IGF-1) SDS, and body mass index were recorded and compared between the two groups before and after treatment to check the treatment efficacy and the influencing factors of clinical efficacy using a multivariate regression model.
RESULTS
The initial dose of rhGH in the GHD group was significantly lower than in the ISS group (P < 0.001). Following rhGH treatment, the differences in CA, BA, BA/CA ratio, and IGF-1 SDS measured at 6, 12, 18, and 24 months between the ISS and GHD groups were not statistically significant, while the difference in HtSDS measured at 6 months was statistically significant.
CONCLUSION
Recombinant human growth hormone treatment can significantly improve the height of patients with ISS and GHD and no significant difference in growth rate between the patients were found at relatively high doses. The common factor affecting the treatment efficacy was the age at the start of treatment. Moreover, a clinical phenomenon in thyroid function is observed in the monitored data during treatment.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Higher levels of HIF2α found to slow down aggressive childhood cancer
2.
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
3.
Guidelines for cervical cancer screening and the risk of preterm birth in young women.
4.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
5.
Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer
1.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
2.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
3.
Progressive Models in Hematology for Healthcare Excellence
4.
Quality of Life Following Organ Function Preserving Oncologic Innovation
5.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge